Last reviewed · How we verify
NCT06584877
Investigating How Childhood Tumours and Congenital Disease Develop
trial testing sample collection in Childhood Tumor in 600 participants. Enrolling by invitation.
28 February 2026
Quick facts
| Lead sponsor | The Wellcome Sanger Institute |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 2 February 2017 |
| Primary completion | 28 February 2026 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- sample collection — full drug profile →
- Seeking consent and assent
Conditions studied
- Childhood Tumor — all drugs for Childhood Tumor →
- Congenital Disorders — all drugs for Congenital Disorders →
Sponsor
The Wellcome Sanger Institute
Who can join
Eligibility, any sex, with Childhood Tumor or Congenital Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Every cell and every organ in the human body derives from a fertilised egg. As the fertilised egg divides, a human being develops and grows. The process of how the fertilised egg divides and forms a human being is very sophisticated and is directed by the genetic information, the DNA, that is present in every cell. When errors, mutations, in the DNA code arise, the orderly process of human development can be disrupted. This can lead to the development of tumours during childhood and congenital diseases (that is, abnormalities that children are born with). The aim of this study is to define exactly which DNA errors underpin childhood tumours and congenital diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06584877
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of sample collection
Trials testing the same drug.
- NCT06832150 — SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues · enrolling by invitation
- NCT05423665 — Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies · recruiting
- NCT06584994 — Investigating the Role of Genetics in Disease Predisposition · enrolling by invitation
- NCT06775457 — Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19) · NA · recruiting
- NCT06497673 — Sanger Human Cell Atlasing Project · enrolling by invitation
Other The Wellcome Sanger Institute trials
Trials by the same sponsor.
- NCT06832150 — SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues · enrolling by invitation
- NCT06656767 — Somatic Mutation in Chronic Liver Disease · enrolling by invitation
- NCT06820294 — Retrospective WGS Study · enrolling by invitation
- NCT06820151 — Exploring the Landscape of Injury and Repair in the Human Oesophagus · enrolling by invitation
- NCT06584994 — Investigating the Role of Genetics in Disease Predisposition · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06584877 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Wellcome Sanger Institute
- Last refreshed: 5 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06584877.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing